Persistent Asset Partners’s Sage Therapeutics SAGE Stock Holding History

Persistent Asset Partners’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-42,216	Closed	-$336K	–	229
2025 Q1	$336K	Sell	42,216 -11,505	-21%	-$84.2K	0.28%	75
2024 Q4	$389K	Buy	+53,721	New	+$328K	0.32%	67

Other funds holding SAGE

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Persistent Asset Partners's SAGE Position: Q2 2025 in Review

Persistent Asset Partners sold out of Sage Therapeutics (SAGE) in Q2 2025, closing a stake of 42,216 shares — an estimated $336K sold.

Persistent Asset Partners first reported a position in SAGE in Q4 2024 and held it in 2 quarters. The position peaked at $389K in Q4 2024. 191 funds tracked by Wall St. Rank hold SAGE as of Q2 2025.

Persistent Asset Partners reported no remaining Sage Therapeutics position as of Q2 2025 after selling out during the quarter.
Persistent Asset Partners sold 42,216 Sage Therapeutics shares in Q2 2025, an estimated $336K.
Persistent Asset Partners first reported a position in Sage Therapeutics in Q4 2024 and held it in 2 quarters.
Persistent Asset Partners's Sage Therapeutics position peaked at $389K in Q4 2024.
191 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2025.

Based on Persistent Asset Partners's 13F filing for Q2 2025, filed 11 Aug 2025.